{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:54:12Z","timestamp":1790463252821,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Jannssen LLC"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.heliyon.2019.e02290","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T20:24:06Z","timestamp":1567196646000},"page":"e02290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model"],"prefix":"10.1016","volume":"5","author":[{"given":"Irfana","family":"Muqbil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Chaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Aboukameel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi M.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asfar S.","family":"Azmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishanan","family":"Ramchandren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2019.e02290_bib1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2019.e02290_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17474086.2018.1449637","article-title":"Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma","volume":"11","author":"Kallam","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.heliyon.2019.e02290_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/asheducation-2017.1.317","article-title":"Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution","volume":"2017","author":"Bartlett","year":"2017","journal-title":"Hematology. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.heliyon.2019.e02290_bib4","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/sj.onc.1203958","article-title":"Signaling network of the Btk family kinases","volume":"19","author":"Qiu","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.heliyon.2019.e02290_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.heliyon.2019.e02290_bib6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/13543784.2017.1349097","article-title":"Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives","volume":"26","author":"Seiler","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.heliyon.2019.e02290_bib7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1078\/0171-2985-00192","article-title":"Bruton's tyrosine kinase is activated upon CD40 stimulation in human B lymphocytes","volume":"206","author":"Brunner","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/j.heliyon.2019.e02290_bib8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.heliyon.2019.e02290_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00428-014-1698-z","article-title":"Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma","volume":"466","author":"Fernandez-Vega","year":"2015","journal-title":"Virchows Arch."},{"key":"10.1016\/j.heliyon.2019.e02290_bib10","doi-asserted-by":"crossref","first-page":"111386","DOI":"10.18632\/oncotarget.22799","article-title":"Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets","volume":"8","author":"Mata","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2019.e02290_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/leu.2016.153","article-title":"Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant","volume":"31","author":"Hamasy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2019.e02290_bib12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2012.074781","article-title":"Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas","volume":"98","author":"Azmi","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2019.e02290_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1756-8722-5-57","article-title":"HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas","volume":"5","author":"Sosin","year":"2012","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2019.e02290_bib14","doi-asserted-by":"crossref","first-page":"16077","DOI":"10.1038\/srep16077","article-title":"Targeting the nuclear export protein XPO1\/CRM1 reverses epithelial to mesenchymal transition","volume":"5","author":"Azmi","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2019.e02290_bib15","first-page":"4950","article-title":"The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model","volume":"6","author":"Mohammad","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2019.e02290_bib16","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.heliyon.2019.e02290_bib17","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1517\/14656566.2010.515979","article-title":"Hodgkin's lymphoma therapy: past, present, and future","volume":"11","author":"Rathore","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.heliyon.2019.e02290_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-017-0383-0","article-title":"Small molecule inhibitors in chronic lymphocytic lymphoma and B cell non-Hodgkin lymphoma","volume":"12","author":"Rosenthal","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.heliyon.2019.e02290_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13046-017-0549-6","article-title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma","volume":"36","author":"Wang","year":"2017","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2019.e02290_bib20","first-page":"561","article-title":"Ibrutinib presents antitumor activity in skin cancer and induces autophagy","volume":"22","author":"Sun","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2019.e02290_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.canlet.2016.09.016","article-title":"Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone","volume":"383","author":"Muqbil","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.heliyon.2019.e02290_bib22","doi-asserted-by":"crossref","first-page":"82144","DOI":"10.18632\/oncotarget.19285","article-title":"Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration","volume":"8","author":"Azmi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2019.e02290_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.13.4.1","article-title":"Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma","volume":"4","author":"Mohammad","year":"2005","journal-title":"Mol. Cancer Ther."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584401935950X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584401935950X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:33:02Z","timestamp":1762511582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584401935950X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S240584401935950X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02290","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e02290"}}